Tezepelumab, a human IgG2 monoclonal antibody that blocks human TSLP, was effective at reducing the rates of asthma exacerbations in patients with moderate to severe disease requiring long-acting beta-antagonists (LABAs) and medium to high doses of ICSs [15]. Here, TSLP is linked to asthma.